Loading resource…

Maurizio Averna, M. Mahmood Hussain, Giuseppe Danilo Norata
Dyslipidaemia and hepatic steatosis are recognized as metabolic disorders that contribute significantly to cardiovascular disease. The article explores various mechanisms that lead to lipid accumulation in the liver, including impaired fatty acid oxidation and the effects of lipid-lowering therapies. It emphasizes the need for careful monitoring of hepatic lipid content in patients undergoing treatment and highlights the potential for new therapeutics that can effectively manage lipid levels without causing steatosis.
No account needed